Programmed cell death-ligand 2: A neglected but important target in the immune response to cancer?
Programmed cell death-ligand 2 (PD-L2) is one of the two ligands of the programmed cell death-1 (PD-1) receptor, an inhibitory protein mainly expressed on activated immune cells that is targeted in the clinic, with successful and remarkable results. The PD-1/PD-Ls axis was shown to be one of the mos...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2020-10-01
|
| Series: | Translational Oncology |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S193652332030303X |
| _version_ | 1828836922875707392 |
|---|---|
| author | Cinzia Solinas Marco Aiello Esdy Rozali Matteo Lambertini Karen Willard-Gallo Edoardo Migliori |
| author_facet | Cinzia Solinas Marco Aiello Esdy Rozali Matteo Lambertini Karen Willard-Gallo Edoardo Migliori |
| author_sort | Cinzia Solinas |
| collection | DOAJ |
| description | Programmed cell death-ligand 2 (PD-L2) is one of the two ligands of the programmed cell death-1 (PD-1) receptor, an inhibitory protein mainly expressed on activated immune cells that is targeted in the clinic, with successful and remarkable results. The PD-1/PD-Ls axis was shown to be one of the most relevant immunosuppressive pathways in the immune microenvironment, and blocking this interaction gave rise to an impressive clinical benefit in a broad variety of solid and hematological malignancies. Although PD-L2 has been historically considered a minor ligand, it binds to PD-1 with a two- to six-fold higher affinity as compared to PD-L1. PD-L2 can be expressed by immune, stromal, or tumor cells. The aims of this narrative review are to summarize PD-L2 biology in the physiological responses of the immune system and its role, expression, and clinical significance in cancer. |
| first_indexed | 2024-12-12T18:30:53Z |
| format | Article |
| id | doaj.art-c424f8953128418eb64eb3ac9e5ef10e |
| institution | Directory Open Access Journal |
| issn | 1936-5233 |
| language | English |
| last_indexed | 2024-12-12T18:30:53Z |
| publishDate | 2020-10-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Translational Oncology |
| spelling | doaj.art-c424f8953128418eb64eb3ac9e5ef10e2022-12-22T00:15:55ZengElsevierTranslational Oncology1936-52332020-10-011310100811Programmed cell death-ligand 2: A neglected but important target in the immune response to cancer?Cinzia Solinas0Marco Aiello1Esdy Rozali2Matteo Lambertini3Karen Willard-Gallo4Edoardo Migliori5Azienda USL Valle d’Aosta, Regional Hospital of Valle d’Aosta, Aosta, ItalyMedical Oncology Unit, A.O.U. Policlinico San Marco, Catania, ItalyDivision of Medical Oncology, National Cancer Centre Singapore, SingaporeIRCCS Ospedale Policlinico San Martino and University of Genova, Genova, ItalyMolecular Immunology Unit, Institut Jules Bordet, Bruxelles, BelgiumColumbia University Medical Center, Columbia Center for Translational Immunology, New York, NY, USA; Address all correspondence to: Edoardo Migliori, Columbia University Medical Center, Columbia Center for Translational Immunology, New York, NY, USA.Programmed cell death-ligand 2 (PD-L2) is one of the two ligands of the programmed cell death-1 (PD-1) receptor, an inhibitory protein mainly expressed on activated immune cells that is targeted in the clinic, with successful and remarkable results. The PD-1/PD-Ls axis was shown to be one of the most relevant immunosuppressive pathways in the immune microenvironment, and blocking this interaction gave rise to an impressive clinical benefit in a broad variety of solid and hematological malignancies. Although PD-L2 has been historically considered a minor ligand, it binds to PD-1 with a two- to six-fold higher affinity as compared to PD-L1. PD-L2 can be expressed by immune, stromal, or tumor cells. The aims of this narrative review are to summarize PD-L2 biology in the physiological responses of the immune system and its role, expression, and clinical significance in cancer.http://www.sciencedirect.com/science/article/pii/S193652332030303X |
| spellingShingle | Cinzia Solinas Marco Aiello Esdy Rozali Matteo Lambertini Karen Willard-Gallo Edoardo Migliori Programmed cell death-ligand 2: A neglected but important target in the immune response to cancer? Translational Oncology |
| title | Programmed cell death-ligand 2: A neglected but important target in the immune response to cancer? |
| title_full | Programmed cell death-ligand 2: A neglected but important target in the immune response to cancer? |
| title_fullStr | Programmed cell death-ligand 2: A neglected but important target in the immune response to cancer? |
| title_full_unstemmed | Programmed cell death-ligand 2: A neglected but important target in the immune response to cancer? |
| title_short | Programmed cell death-ligand 2: A neglected but important target in the immune response to cancer? |
| title_sort | programmed cell death ligand 2 a neglected but important target in the immune response to cancer |
| url | http://www.sciencedirect.com/science/article/pii/S193652332030303X |
| work_keys_str_mv | AT cinziasolinas programmedcelldeathligand2aneglectedbutimportanttargetintheimmuneresponsetocancer AT marcoaiello programmedcelldeathligand2aneglectedbutimportanttargetintheimmuneresponsetocancer AT esdyrozali programmedcelldeathligand2aneglectedbutimportanttargetintheimmuneresponsetocancer AT matteolambertini programmedcelldeathligand2aneglectedbutimportanttargetintheimmuneresponsetocancer AT karenwillardgallo programmedcelldeathligand2aneglectedbutimportanttargetintheimmuneresponsetocancer AT edoardomigliori programmedcelldeathligand2aneglectedbutimportanttargetintheimmuneresponsetocancer |